<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>References | Quantifying Experiences made during Altered States of Consciousness with Questionnaires</title>
  <meta name="description" content="References | Quantifying Experiences made during Altered States of Consciousness with Questionnaires" />
  <meta name="generator" content="bookdown 0.42 and GitBook 2.6.7" />

  <meta property="og:title" content="References | Quantifying Experiences made during Altered States of Consciousness with Questionnaires" />
  <meta property="og:type" content="book" />
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="References | Quantifying Experiences made during Altered States of Consciousness with Questionnaires" />
  
  
  

<meta name="author" content="Dr. Timo Torsten Schmidt, Circe e.V." />


<meta name="date" content="2025-03-22" />

  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="questionnaires-for-subacute-asc-phenomena.html"/>
<link rel="next" href="todos.html"/>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.1.0/anchor-sections.css" rel="stylesheet" />
<link href="libs/anchor-sections-1.1.0/anchor-sections-hash.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.1.0/anchor-sections.js"></script>



<style type="text/css">
  
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
</style>
<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">Consciousness Assessment Repository</a></li>

<li class="divider"></li>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Preface</a></li>
<li class="chapter" data-level="" data-path="acknowledgements.html"><a href="acknowledgements.html"><i class="fa fa-check"></i>Acknowledgements</a></li>
<li class="chapter" data-level="1" data-path="introduction.html"><a href="introduction.html"><i class="fa fa-check"></i><b>1</b> Introduction</a>
<ul>
<li class="chapter" data-level="1.1" data-path="introduction.html"><a href="introduction.html#overview"><i class="fa fa-check"></i><b>1.1</b> Overview</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html"><i class="fa fa-check"></i><b>2</b> Questionnaires for acute ASC phenomena</a>
<ul>
<li class="chapter" data-level="2.1" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#altered-states-of-consciousness-rating-scales-asc-r"><i class="fa fa-check"></i><b>2.1</b> Altered States of Consciousness Rating Scales (ASC-R)</a>
<ul>
<li class="chapter" data-level="2.1.1" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#apz"><i class="fa fa-check"></i><b>2.1.1</b> APZ</a></li>
<li class="chapter" data-level="2.1.2" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#oav"><i class="fa fa-check"></i><b>2.1.2</b> OAV</a></li>
<li class="chapter" data-level="2.1.3" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#d-asc-or-oavav"><i class="fa fa-check"></i><b>2.1.3</b> 5D-ASC (or OAVAV)</a></li>
<li class="chapter" data-level="2.1.4" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#asc"><i class="fa fa-check"></i><b>2.1.4</b> 11-ASC</a></li>
<li class="chapter" data-level="2.1.5" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#short-versions"><i class="fa fa-check"></i><b>2.1.5</b> Short Versions</a></li>
<li class="chapter" data-level="2.1.6" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#important-notes"><i class="fa fa-check"></i><b>2.1.6</b> Important notes</a></li>
<li class="chapter" data-level="2.1.7" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#validation-translations-adaptations-and-future-developments"><i class="fa fa-check"></i><b>2.1.7</b> Validation, Translations, Adaptations and Future Developments</a></li>
</ul></li>
<li class="chapter" data-level="2.2" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#ego-dissolution-inventory-edi"><i class="fa fa-check"></i><b>2.2</b> Ego-Dissolution Inventory (EDI)</a></li>
<li class="chapter" data-level="2.3" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#emotional-breakthrough-inventory-ebi"><i class="fa fa-check"></i><b>2.3</b> Emotional Breakthrough Inventory (EBI)</a></li>
<li class="chapter" data-level="2.4" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#phenomenology-of-consciousness-inventory-pci"><i class="fa fa-check"></i><b>2.4</b> Phenomenology of Consciousness Inventory (PCI)</a></li>
<li class="chapter" data-level="2.5" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#hallucinogen-rating-scale-hrs"><i class="fa fa-check"></i><b>2.5</b> Hallucinogen Rating Scale (HRS)</a></li>
<li class="chapter" data-level="2.6" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#mystical-experience-questionnaire-meq"><i class="fa fa-check"></i><b>2.6</b> Mystical Experience Questionnaire (MEQ)</a>
<ul>
<li class="chapter" data-level="2.6.1" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#states-of-consciousness-questionnaire-socq"><i class="fa fa-check"></i><b>2.6.1</b> States of Consciousness Questionnaire (SOCQ)</a></li>
<li class="chapter" data-level="2.6.2" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#psychedelic-experience-scale-pes"><i class="fa fa-check"></i><b>2.6.2</b> Psychedelic Experience Scale (PES)</a></li>
<li class="chapter" data-level="2.6.3" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#meq30"><i class="fa fa-check"></i><b>2.6.3</b> MEQ30</a></li>
<li class="chapter" data-level="2.6.4" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#meq-4"><i class="fa fa-check"></i><b>2.6.4</b> MEQ-4</a></li>
<li class="chapter" data-level="2.6.5" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#validation-translations-adaptations"><i class="fa fa-check"></i><b>2.6.5</b> Validation, Translations, Adaptations</a></li>
</ul></li>
<li class="chapter" data-level="2.7" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#challenging-experience-questionnaire-ceq"><i class="fa fa-check"></i><b>2.7</b> Challenging Experience Questionnaire (CEQ)</a>
<ul>
<li class="chapter" data-level="2.7.1" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#ceq-7"><i class="fa fa-check"></i><b>2.7.1</b> CEQ-7</a></li>
</ul></li>
<li class="chapter" data-level="2.8" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#psychological-insight-questionnaire-piq"><i class="fa fa-check"></i><b>2.8</b> Psychological Insight Questionnaire (PIQ)</a></li>
<li class="chapter" data-level="2.9" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#watts-connectedness-scale-wcs"><i class="fa fa-check"></i><b>2.9</b> Watts Connectedness Scale (WCS)</a></li>
<li class="chapter" data-level="2.10" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#psychotomimetic-states-inventory-psi"><i class="fa fa-check"></i><b>2.10</b> Psychotomimetic States Inventory (PSI)</a></li>
<li class="chapter" data-level="2.11" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#abramson-questionnaire-aq"><i class="fa fa-check"></i><b>2.11</b> Abramson Questionnaire (AQ)</a></li>
<li class="chapter" data-level="2.12" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#linton-langs-questionnaire-llq"><i class="fa fa-check"></i><b>2.12</b> Linton &amp; Langs Questionnaire (LLQ)</a></li>
<li class="chapter" data-level="2.13" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#near-death-experience-scale-nde-scale"><i class="fa fa-check"></i><b>2.13</b> Near-Death Experience Scale (NDE scale)</a></li>
<li class="chapter" data-level="2.14" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#the-mysticism-scale-m-scale"><i class="fa fa-check"></i><b>2.14</b> The Mysticism Scale (M-Scale)</a></li>
<li class="chapter" data-level="2.15" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#personal-experiences-questionnaire-peq"><i class="fa fa-check"></i><b>2.15</b> Personal Experiences Questionnaire (PEQ)</a></li>
<li class="chapter" data-level="2.16" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#assessment-schedule-of-altered-states-for-consciousness-asacs"><i class="fa fa-check"></i><b>2.16</b> Assessment Schedule of Altered States for Consciousness (ASACS)</a></li>
<li class="chapter" data-level="2.17" data-path="questionnaires-for-acute-asc-phenomena.html"><a href="questionnaires-for-acute-asc-phenomena.html#addiction-research-center-inventory-arci"><i class="fa fa-check"></i><b>2.17</b> Addiction Research Center Inventory (ARCI)</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="questionnaires-for-subacute-asc-phenomena.html"><a href="questionnaires-for-subacute-asc-phenomena.html"><i class="fa fa-check"></i><b>3</b> Questionnaires for subacute ASC phenomena</a>
<ul>
<li class="chapter" data-level="3.1" data-path="questionnaires-for-subacute-asc-phenomena.html"><a href="questionnaires-for-subacute-asc-phenomena.html#afterglow-inventory-agi"><i class="fa fa-check"></i><b>3.1</b> Afterglow Inventory (AGI)</a></li>
<li class="chapter" data-level="3.2" data-path="questionnaires-for-subacute-asc-phenomena.html"><a href="questionnaires-for-subacute-asc-phenomena.html#persisting-effects-questionnaire-peq"><i class="fa fa-check"></i><b>3.2</b> Persisting Effects Questionnaire (PEQ)</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="references.html"><a href="references.html"><i class="fa fa-check"></i>References</a></li>
<li class="chapter" data-level="" data-path="todos.html"><a href="todos.html"><i class="fa fa-check"></i>ToDo’s</a></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Quantifying Experiences made during Altered States of Consciousness with Questionnaires</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="references" class="section level1 unnumbered hasAnchor">
<h1>References<a href="references.html#references" class="anchor-section" aria-label="Anchor link to header"></a></h1>
<div id="refs" class="references csl-bib-body hanging-indent">
<div class="csl-entry">
Abramson HA, Jarvik ME, Levine A, Kaufman MR, Hirsch MW (1955) Lysergic acid diethylamide (<span>LSD</span>-25): <span>XV</span>. <span>The</span> effects produced by substitution of a tap water placebo. Journal of Psychology 40:367–383.
</div>
<div class="csl-entry">
Arasteh K, Poudevida S, Farré M, Roset PN, Camí J (1999) Response patterns of the <span>Spanish</span> version of the 49-item short form of the <span>Addiction</span> <span>Research</span> <span>Center</span> <span>Inventory</span> after the use of sedatives, stimulants, and opioids. Drug and Alcohol Dependence 55:117–125.
</div>
<div class="csl-entry">
Barrett FS, Johnson MW, Griffiths RR (2015) <a href="https://doi.org/10.1177/0269881115609019">Validation of the revised <span>Mystical</span> <span>Experience</span> <span>Questionnaire</span> in experimental sessions with psilocybin</a>. Journal of Psychopharmacology.
</div>
<div class="csl-entry">
Bodmer I (1989) Konstruktion des <span>Fragebogens</span> <span>OAV</span> zur quantitativen <span>Erfassung</span> aussergewöhnlicher <span>Bewusstseinszustände</span> (<span>ABZ</span>) [<span>Construction</span> of the questionnaire <span>OAV</span> for the quantitative assessment of altered states of consciousness].
</div>
<div class="csl-entry">
Bodmer I, Dittrich A, Lamparter D (1994) Aussergewöhnliche <span>Bewusstseinszustände</span> - <span>Ihre</span> gemeinsame <span>Struktur</span> und <span>Messung</span> [<span>Altered</span> states of consciousness - <span>Their</span> common structure and assessment]. In: Welten des <span>Bewusstseins</span>. <span>Bd</span>. 3 (Hofmann A, Leuner H, eds), pp 45–58. Berlin, Germany: Experimentelle Psychologie, Neurobiologie und Chemie.
</div>
<div class="csl-entry">
Bouso JC, Pedrero-Perez EJ, Candy S, Alcazar-Corcoles MA (2016) Measuring the subjective: Revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens. Journal of Clinical Psychiatry:391–393.
</div>
<div class="csl-entry">
Bowdle T, Radant A, Cowley D, Kharasch E, Strassman R, Roy-Byrne P (1998) Psychedelic effects of ketamine in healthy volunteers: Relationship to steady-state plasma concentrations.
</div>
<div class="csl-entry">
Carhart-Harris R et al (2016) Neural correlates of the <span>LSD</span> experience revealed by multimodal neuroimaging. Proc Natl Acad Sci.
</div>
<div class="csl-entry">
Carhart-Harris R, Kaelen M, Bolstridge M, Williams T, Williams L, Underwood R, Feilding A, Nutt D (2016) The paradoxical psychological effects of lysergic acid diethylamide (<span>LSD</span>). :1379–1390.
</div>
<div class="csl-entry">
Daniel C, Lovatt A, Mason O (2014) Psychotic-like experiences and their cognitive appraisal under short-term sensory deprivation. Front Psychiatry 5:106.
</div>
<div class="csl-entry">
Daniel C, Mason O (2015) Predicting psychotic-like experiences during sensory deprivation. Biomed Res Int 2015.
</div>
<div class="csl-entry">
Davis AK, Barrett FS, So S, Gukasyan N, Swift TC, Griffiths RR (2021) Development of the <span>Psychological</span> <span>Insight</span> <span>Questionnaire</span> among a sample of people who have consumed psilocybin or <span>LSD</span>. Journal of Psychopharmacology 35:437–446 Available at: <a href="https://doi.org/10.1177/0269881120967878">https://doi.org/10.1177/0269881120967878</a>.
</div>
<div class="csl-entry">
Dittrich A (1985) Ätiologie-unabhängige <span>Strukturen</span> veränderter <span>Wachbewusstseinszustände</span>.
</div>
<div class="csl-entry">
Dittrich A, Lamparter D, Maurer M (2006) <span>5D</span>-<span>ABZ</span>: <span>Fragebogen</span> zur <span>Erfassung</span> <span>Aussergewöhnlicher</span> <span>Bewusstseinszustände</span>. <span>Eine</span> kurze <span>Einführung</span>. Zürich, Switzerland.
</div>
<div class="csl-entry">
Dittrich A, Lamparter D, Maurer M (2010) <span>5D</span>-<span>ASC</span>: <span>Questionnaire</span> for the assessment of altered states of consciousness. <span>A</span> short introduction (3rd ed.). Zürich, Switzerland: PSIN PLUS.
</div>
<div class="csl-entry">
Doblin R (1991) Pahnke’s <span>“<span>Good</span> <span>Friday</span> experiment”</span> - <span>A</span> long-term follow-up and methodological critique. J Transpers Psychol 23:1–28.
</div>
<div class="csl-entry">
Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, Arning C, Thelen B, Spitzer M, Kovar K, Hermle L, Bull U, Sass H (1999) Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (<span>MDE</span>) and d-methamphetamine in healthy volunteers. <span>A</span> double-blind, placebo-controlled <span>PET</span> study with [<span>18F</span>]<span>FDG</span>. Neuropsychopharmacology 20:565–581.
</div>
<div class="csl-entry">
Greyson B (1983) The near-death experience scale: <span>Construction</span>, reliability, and validity. Journal of Nervous and Mental Disease 171:369–375 Available at: <a href="https://doi.org/10.1097/00005053-198306000-00007">https://doi.org/10.1097/00005053-198306000-00007</a>.
</div>
<div class="csl-entry">
Griffiths R, Johnson M, Richards W, Richards B, McCann U, Jesse R (2011) Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology (Berl) 218:649–665.
</div>
<div class="csl-entry">
Griffiths R, Richards W, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187:268-283-292.
</div>
<div class="csl-entry">
Haertzen C (1974) An overview of addiction research center inventory scales (<span>ARCI</span>): <span>Appendix</span> and manual of scales. Rockville: National Institute of Drug Abuse.
</div>
<div class="csl-entry">
Haertzen C, Hickey J (1987) Addiction <span>Research</span> <span>Center</span> <span>Inventory</span> (<span>ARCI</span>): <span>Measurement</span> of euphoria and other drug effects. In: Methods of assessing the reinforcing properties of abused drugs (Bozarth M, ed), pp 489–524. New York: Springer.
</div>
<div class="csl-entry">
Haertzen C, Hill H, Belleville R (1963) Development of the <span>Addiction</span> <span>Research</span> <span>Center</span> <span>Inventory</span> (<span>ARCI</span>): <span>Selection</span> of items that are sensitive to the effects of various drugs. Psychopharmacologia 4:155–166.
</div>
<div class="csl-entry">
Hill H, Haertzen C, Wolbach A, Miner E (1963a) The <span>Addictive</span> <span>Research</span> <span>Center</span> <span>Inventory</span>: <span>Appendix</span> <span>I</span>. <span>Items</span> <span>Comprising</span> <span>Empirical</span> <span>Scales</span> for <span>Seven</span> <span>Drugs</span> <span>II</span>. <span>Items</span> which <span>Do</span> <span>Not</span> <span>Differentiate</span> <span>Placebo</span> from any <span>Drug</span> <span>Condition</span>. Psychopharmacologia 4:184–205.
</div>
<div class="csl-entry">
Hill H, Haertzen C, Wolbach A, Miner E (1963b) The <span>Addiction</span> <span>Research</span> <span>Center</span> <span>Inventory</span>: <span>Standardization</span> of scales which evaluate subjective effects of morphine, amphetamine, pentobarbital, alcohol, <span>LSD</span>-25, pyrahexyl and chlorpromazine. Psychopharmacologia 4:167–183.
</div>
<div class="csl-entry">
Hirschfeld T, Prugger J, Majić T, Schmidt TT (2023) Dose-response relationships of <span>LSD</span>-induced subjective experiences in humans. Neuropsychopharmacology 48:1602–1611 Available at: <a href="https://doi.org/10.1038/s41386-023-01588-2">https://doi.org/10.1038/s41386-023-01588-2</a>.
</div>
<div class="csl-entry">
Hirschfeld T, Schmidt TT (2021) Dose-response relationships of psilocybin-induced subjective experiences in humans. Journal of Psychopharmacology 35:384–397 Available at: <a href="https://doi.org/10.1177/0269881121992676">https://doi.org/10.1177/0269881121992676</a>.
</div>
<div class="csl-entry">
Hood R (1975) The construction and preliminary validation of a measure of reported mystical experience. J Sci Study Relig 14:29–41.
</div>
<div class="csl-entry">
Hood R, Ghorbani N, Watson P, Ghramaleki A, Bing M, Davison H, Morris R, Williamson W (2001) Dimensions of the <span>Mysticism</span> <span>Scale</span>: <span>Confirming</span> the <span>Three</span>-<span>Factor</span> <span>Structure</span> in the <span>United</span> <span>States</span> and <span>Iran</span>. J Sci Study Relig 40:691–705.
</div>
<div class="csl-entry">
James W (1901) Varieties of religious experience. New York: New American Library.
</div>
<div class="csl-entry">
Jarvik ME, Abramson HA, Hirsch MW (1955) Comparative subjective effects of seven drugs including lysergic acid diethylamide (<span>LSD</span>-25). Journal of Abnormal Psychology 51:657–662 Available at: <a href="https://doi.org/10.1037/h0041073">https://doi.org/10.1037/h0041073</a>.
</div>
<div class="csl-entry">
Jasinski D, Martin W, Hoeldtke R (1971) Studies of the dependence-producing properties of <span>GPA</span>-1657, profadol and proplram in man. Clin Pharmacol Ther 12:613–649.
</div>
<div class="csl-entry">
Johnson M, MacLean K, Reissig C, Prisinzano T, Griffiths R (2011) Human psychopharmacology and dose-effects of salvinorin <span>A</span>, a kappa opioid agonist hallucinogen present in the plant <span>Salvia</span> divinorum. Drug Alcohol Depend 115:150–155.
</div>
<div class="csl-entry">
Kjellgren A, Lindahl A, Norlander T (2009) Altered states of consciousness and mystical experiences during sensory isolation in flotation tank: <span>Is</span> the highly sensitive personality variable of importance? IMAGINATION, Cogn Personal 29:135–146.
</div>
<div class="csl-entry">
Kjellgren A, Sundequist U, Norlander T, Archer T (2001) Effects of flotation-<span>REST</span> on muscle tension pain. Pain Res Manag 6:181–189.
</div>
<div class="csl-entry">
Lamas X, Farré M, Llorente M, Camí J (1994) Spanish version of the 49-item short form of the <span>Addiction</span> <span>Research</span> <span>Center</span> inventory. Drug Alcohol Depend 35:203–209.
</div>
<div class="csl-entry">
Lebedev A, Lövdén M, Rosenthal G, Feilding A, Nutt D, Carhart-Harris R (2015) Finding the self by losing the self: <span>Neural</span> correlates of ego-dissolution under psilocybin. Hum Brain Mapp 36:3137–3153.
</div>
<div class="csl-entry">
Linton H, Langs R (1962) Placebo <span>Reaction</span> in a <span>Study</span> of <span>Lysergic</span> <span>Acid</span> <span>Diethylamide</span> (<span>LSD</span>-25). Arch Gen Psychiatry.
</div>
<div class="csl-entry">
MacLean K, Johnson M, Griffiths R (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25:1453–1461.
</div>
<div class="csl-entry">
MacLean K, Leoutsakos J-M, Johnson M, Griffiths R (2012) Factor <span>Analysis</span> of the <span>Mystical</span> <span>Experience</span> <span>Questionnaire</span>: <span>A</span> <span>Study</span> of <span>Experiences</span> <span>Occasioned</span> by the <span>Hallucinogen</span> <span>Psilocybin</span>. J Sci Study Relig 51:721–737.
</div>
<div class="csl-entry">
Majic T, Schmidt T, Gallinat J (2015) Peak experiences and the afterglow phenomenon: <span>When</span> and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J Psychopharmacol 29:241–253.
</div>
<div class="csl-entry">
Martin W, Sloan J, Sapira J, Jasinski D (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245–258.
</div>
<div class="csl-entry">
Mason O, Brady F (2009) The psychotomimetic effects of short-term sensory deprivation. J Nerv Ment Dis 197:783–785.
</div>
<div class="csl-entry">
Mason O, Morgan C, Stefanovic A, Curran H (2008) The <span>Psychotomimetic</span> <span>States</span> <span>Inventory</span> (<span>PSI</span>): <span>Measuring</span> psychotic-type experiences from ketamine and cannabis. Schizophr Res 103:138–142.
</div>
<div class="csl-entry">
Nour M, Evans L, Nutt D, Carhart-Harris R (2016) Ego-<span>Dissolution</span> and <span>Psychedelics</span>: <span>Validation</span> of the <span>Ego</span>-<span>Dissolution</span> <span>Inventory</span> (<span>EDI</span>). Front Hum Neurosci 10:269 Available at: <a href="http://www.ncbi.nlm.nih.gov/pubmed/27378878">http://www.ncbi.nlm.nih.gov/pubmed/27378878</a>.
</div>
<div class="csl-entry">
Pahnke WN (1963) Drugs and mysticism: <span>An</span> analysis of the relationship between psychedelic drugs and the mystical consciousness. Harvard University Press.
</div>
<div class="csl-entry">
Pahnke WN (1966) Drugs and <span>Mysticism</span>. Int J Parapsychol 8:295–314.
</div>
<div class="csl-entry">
Peill JM, Trinci KE, Kettner H, Mertens LJ, Roseman L, Timmermann C, Rosas FE, Lyons T, Carhart-Harris RL (2022) Validation of the <span>Psychological</span> <span>Insight</span> <span>Scale</span>: <span>A</span> new scale to assess psychological insight following a psychedelic experience. Journal of Psychopharmacology 36:31–45 Available at: <a href="https://doi.org/10.1177/02698811211066709">https://doi.org/10.1177/02698811211066709</a>.
</div>
<div class="csl-entry">
Pekala R (1982) The <span>Phenomenology</span> of <span>Consciousness</span> <span>Inventory</span>. Thorndale, PA: Psychophenomenological Concepts.
</div>
<div class="csl-entry">
Pekala R (1991) Quantifying <span>Consciousness</span>: <span>An</span> <span>Empirical</span> <span>Approach</span>. New York: Plenum Press.
</div>
<div class="csl-entry">
Pekala R (1995) A <span>Short</span>, <span>Unobtrusive</span> <span>Hypnotic</span>-<span>Assessment</span> <span>Procedure</span> for <span>Assessing</span> <span>Hypnotizability</span> <span>Level</span>: <span>I</span>. <span>Development</span> and <span>Research</span>. Am J Clin Hypn 37:271–283.
</div>
<div class="csl-entry">
Riba J, Anderer P, Jané F, Saletu B, Barbanoj MJ (2004) Effects of the <span>South</span> <span>American</span> psychoactive beverage <span>Ayahuasca</span> on regional brain electrical activity in humans: <span>A</span> functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology 50:89–101.
</div>
<div class="csl-entry">
Riba J, Rodríguez-Fornells A, Strassman RJ, Barbanoj MJ (2001) Psychometric assessment of the <span>Hallucinogen</span> <span>Rating</span> <span>Scale</span>. Drug Alcohol Depend 62:215–223.
</div>
<div class="csl-entry">
Roseman L, Haijen E, Idialu-Ikato K, Kaelen M, Watts R, Carhart-Harris R (2019) Emotional breakthrough and psychedelics: <span>Validation</span> of the <span>Emotional</span> <span>Breakthrough</span> <span>Inventory</span>. Journal of Psychopharmacology 33:1076–1087 Available at: <a href="https://doi.org/10.1177/0269881119855974">https://doi.org/10.1177/0269881119855974</a>.
</div>
<div class="csl-entry">
Rux (2002) Erprobung der deutschen übersetzung des <span>Phenomenology</span> of <span>Consciousness</span> <span>Inventory</span> von <span>Pekala</span>: <span>Normwerte</span>, <span>Gütekriterien</span>, änderungsvorschläge.
</div>
<div class="csl-entry">
Scharfetter C (1981) Ego-psychopathology: The concept and its empirical evaluation. Psychol Med 11:273–280.
</div>
<div class="csl-entry">
Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Müller F, Borgwardt S, Liechti ME (2015) Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry 78:544–553.
</div>
<div class="csl-entry">
Shor RE (1960) The frequency of naturally occurring <span>“hypnotic-like”</span> experiences in the normal college population. Int J Clin Exp Hypn 8:151–163.
</div>
<div class="csl-entry">
Stocker K, Hartmann M, Ley L, Becker AM, Holze F, Liechti ME (2024) The revival of the psychedelic experience scale: <span>Revealing</span> its extended-mystical, visual, and distressing experiential spectrum with <span>LSD</span> and psilocybin studies. Journal of Psychopharmacology 38:80–100 Available at: <a href="https://doi.org/10.1177/02698811231199112">https://doi.org/10.1177/02698811231199112</a>.
</div>
<div class="csl-entry">
Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose-response study of <span>N</span>,<span>N</span>-dimethyltryptamine in humans. <span>II</span>. <span>Subjective</span> effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98–108.
</div>
<div class="csl-entry">
Strickland JC, Garcia-Romeu A, Johnson MW (2024) <a href="https://doi.org/10.1089/psymed.2023.0046">The <span>Mystical</span> <span>Experience</span> <span>Questionnaire</span> 4-<span>Item</span> and <span>Challenging</span> <span>Experience</span> <span>Questionnaire</span> 7-<span>Item</span></a>. Psychedelic Medicine 2:33–43.
</div>
<div class="csl-entry">
Studerus E, Gamma A, Kometer M, Vollenweider FX (2012) Prediction of <span>Psilocybin</span> <span>Response</span> in <span>Healthy</span> <span>Volunteers</span>. PLoS One 7:e30800.
</div>
<div class="csl-entry">
Studerus E, Gamma A, Vollenweider FX (2010) <a href="https://doi.org/10.1371/journal.pone.0012412">Psychometric evaluation of the altered states of consciousness rating scale (<span>OAV</span>)</a>. PLoS One 5:e12412.
</div>
<div class="csl-entry">
Tagliazucchi E, Roseman L, Kaelen M, Orban C, Muthukumaraswamy SD, Murphy K, Laufs H, Leech R, McGonigle J, Crossley N, Bullmore E, Williams T, Bolstridge M, Feilding A, Nutt DJ, Carhart-Harris R (2016) Increased <span>Global</span> <span>Functional</span> <span>Connectivity</span> <span>Correlates</span> with <span>LSD</span>-<span>Induced</span> <span>Ego</span> <span>Dissolution</span>. Curr Biol 26:1043–1050.
</div>
<div class="csl-entry">
Tancer ME, Johanson C-E (2007) The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (<span>MDMA</span>) in humans. Psychopharmacol 189:565–573.
</div>
<div class="csl-entry">
Tart CT (1972) States of <span>Consciousness</span> and <span>State</span>-<span>Specific</span> <span>Sciences</span>. Science 176:1203–1210.
</div>
<div class="csl-entry">
Van Quekelberghe R, Altstötter-Gleich C, Hertweck E (1991) Assessment schedule for altered states of consciousness: <span>A</span> brief report. Journal of Parapsychology 55:377–390.
</div>
<div class="csl-entry">
Van Quekelberghe R, Schreiber WH, Peter M, Caprano G (1992) Erfassungssystem veränderter <span>Bewußtseinszustände</span> (<span>EVB</span>): <span>Darstellung</span> des <span>Verfahrens</span> und der <span>Ergebnisse</span> aus den <span>Vergleichsuntersuchungen</span> zwischen <span>Normalen</span>, <span>Heroinabhängigen</span>, <span>Depressiven</span> und <span>Schizophrenen</span>. Forschungsberichte des FB Psychologie, Universität Koblenz-Landau.
</div>
<div class="csl-entry">
Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci 11:642–651.
</div>
<div class="csl-entry">
Warot D, Danjou P, Payan C, Puech AJ (1997) Sensitivity and specificity to amphetamine of a <span>French</span> version of the 49-item form of the <span>Addiction</span> <span>Research</span> <span>Center</span> <span>Inventory</span>. Drug Alcohol Depend 45:177–183.
</div>
<div class="csl-entry">
Watts R, Kettner H, Geerts D, Gandy S, Kartner L, Mertens L, Timmermann C, Nour MM, Kaelen M, Nutt D, Carhart-Harris R, Roseman L (2022) The <span>Watts</span> <span>Connectedness</span> <span>Scale</span>: A new scale for measuring a sense of connectedness to self, others, and world. Psychopharmacology (Berl) 239:3461–3483 Available at: <a href="https://doi.org/10.1007/s00213-022-06187-5">https://doi.org/10.1007/s00213-022-06187-5</a>.
</div>
<div class="csl-entry">
Yeginer A (2000) Forschungsinstrumente der <span>Transpersonalen</span> <span>Psychologie</span>.
</div>
</div>

</div>
            </section>

          </div>
        </div>
      </div>
<a href="questionnaires-for-subacute-asc-phenomena.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="todos.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/circe-e-v.github.io/CAR/edit/main/05-References.Rmd",
"text": "Edit"
},
"history": {
"link": null,
"text": null
},
"view": {
"link": "https://github.com/circe-e-v.github.io/CAR/blob/main/05-References.Rmd",
"text": null
},
"download": null,
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "subsection"
}
});
});
</script>

</body>

</html>
